Citizens initiated coverage of Opus Genetics (IRD) with an Outperform rating and $12 price target The company is developing a portfolio of AAV-based gene therapies for inherited retinal diseases, with the goal of preserving and/or restoring vision in patients who lack any treatments today, the analyst tells investors in a research note. The firm says Opus’ inherited retinal disease focus provides multiple benefits for a large commercial opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics management to meet with Piper Sandler
- Opus Genetics Secures $155 Million Senior Note Financing
- Opus Genetics: Undervalued Gene Therapy Play on Upcoming Retinal Disease Data Catalysts
- Opus Genetics Shareholders Approve Governance and Capital Changes
- Opus Genetics management to meet with B. Riley